Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7352870 | 0.98 | CA2 (0.41) | CA2ATRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3105631 | 0.92 | ATR (0.39) | CA2ATRALDH1A1GRIA1 | |
| SCHEMBL3116195 | 0.81 | — | — | |
| 1,4-Butanediol SCHEMBL7623431 | 0.78 | GRIA1 (0.40) | CA2ATRSMN1; SMN2LMNAALDH1A1 | |
| 1,4-Butanediol SCHEMBL28294560 | 0.78 | GRIA1 (0.40) | CA2ATRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL5505478 | 0.77 | CA2 (0.59) | CA2SMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL3117978 | 0.77 | CA2 (0.39) | CA2GRIA1 | |
| SCHEMBL13588751 | 0.76 | GRIA1 (0.33) | ATRGRIA1 | |
| SCHEMBL14519882 | 0.75 | CA2 (0.63) | CA2TSHR | |
| SCHEMBL1911477 | 0.75 | CA2 (0.63) | CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222417-B2 | Compound having 11β-HSD1 inhibitory activity | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100179325-A1 | COMPOUND HAVING 11BETA-HSD1 INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2172453-A1 | COMPOUND HAVING 11 ß-HSD1 INHIBITORY ACTIVITY | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179325-A1 | COMPOUND HAVING 11BETA-HSD1 INHIBITORY ACTIVITY | HSD11B1, CYP4A11, HSD11B2 | CA2 571/4885ATR 4439/4885SMN1; SMN2 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.